Similar to overall survival, high MARCHF9 expression was associated with a significantly worse disease-specific survival outcome for COAD and READ cases in the TCGA cohort (Figure 2(b), P < 0.05), strengthening the evidence for its prognostic significance in CRC. This evidence concerns the gene MARCHF9 and colon adenocarcinoma.